• Self-Assembling EVMPs for Extrahepatic mRNA Delivery

  2026-08-30

  The reference study introduces enveloped virus-mimicking particles (EVMPs), a bottom-up platform that combines self-assembling peptides with tunable phospholipid envelopes for mRNA delivery to organs beyond the liver. Optimized formulations targeted lung and spleen tissues, achieved defined lung-cell transfection, and suppressed metastatic lung tumors when loaded with IL-12 mRNA, while showing a profile compatible with repeated administration in preclinical testing.

• BI 2536: PLK1 Inhibitor Workflow Guide

  2026-08-29

  BI 2536 is a selective PLK1 inhibitor for separating mitotic arrest, growth suppression, and cell death in cancer models. This guide translates its biochemical profile into practical assay design, quantitative readouts, troubleshooting strategies, and cautious in vitro-to-tumor xenograft interpretation.

• DRB at the Transcription–Translation Interface

  2026-08-28

  A translational framework for using 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) to connect RNA polymerase II elongation, CDK signaling, and YTHDF1-driven stem cell fate transitions.

• Olaparib (AZD2281): Reliable Assay Workflows

  2026-08-28

  A practical, scenario-based guide to using Olaparib (AZD2281, Ku-0059436), SKU A4154, in cell viability, DNA damage response, and tumor radiosensitization studies. It covers solvent compatibility, assay controls, concentration planning, interpretation, and evidence-based product selection.

• MEDUSA Reveals How Drugs Trigger Cell Death

  2026-08-27

  Honeywell et al. introduce MEDUSA, a simulation-assisted method that separates drug-induced changes in cell growth from changes in cell death during pooled functional genomic screens. Applied to DNA damage, the approach shows that loss of p53 redirects lethality from apoptosis toward a nonapoptotic, respiration-dependent death program, providing a stronger framework for interpreting drug sensitivity and resistance.

• RG108 in Mouse Germline-Like Differentiation

  2026-08-27

  This study established a chemical and culture-based protocol that generated mouse embryonic stem cell derivatives with spermatogonia-like morphology and increased population-level Lhx1 expression. RG108 contributed to a combined intervention associated with rare cells showing strong nuclear LHX1/5 protein, but the findings support a cocktail-dependent developmental effect rather than an isolated RG108 mechanism.

• SGC-CBP30 for CREBBP/EP300 Research

  2026-08-26

  SGC-CBP30 provides a selective way to test how CREBBP and EP300 bromodomain activity shapes enhancer-driven transcription. This practical guide translates super-enhancer and TGF-β/SMAD3 findings into controllable workflows for epigenetics research, cancer biology research, and exploratory lung adenocarcinoma research.

• WM-8014: A Practical KAT6A Inhibitor Workflow

  2026-08-26

  WM-8014 combines potent, reversible KAT6A/B inhibition with a practical route to study cell-cycle arrest, senescence, and oncogenic proliferation. This guide connects dose finding, phenotype validation, and time-gated CRISPR screening while addressing solubility and translational limitations.

• Sulforaphane, ROS, and NLRP3 in Ulcerative Colitis

  2026-08-25

  A 2024 Biomedicine & Pharmacotherapy study shows that Sulforaphane reduces oxidative stress and suppresses NLRP3 inflammasome-associated inflammation in dextran sulfate sodium-induced mouse colitis. Its combined animal and RAW264.7-cell experiments support ROS control as a mechanistic link, while also highlighting the limits of translating an acute mouse model into human ulcerative colitis.

• Gastric Cancer Assembloids Reveal Tumor–Stroma Biology

  2026-08-25

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations. The model reproduced key epithelial–stromal interactions, altered transcriptional states, and drug-response differences that were not visible in organoid monocultures, supporting more physiologically relevant personalized drug testing.

• Deferasirox Fe3+ Chelate in Cell Assays

  2026-08-24

  A scenario-based guide to using Deferasirox Fe3+ chelate (SKU A3355) in cell viability, proliferation, and cytotoxicity workflows. It explains ferric-complex interpretation, solvent compatibility, protocol controls, mechanistic readouts, and practical vendor-selection criteria using product specifications and recent hematopoiesis research.

• Ro 3306: A Temporal Probe of CDK1 and DNA Repair

  2026-08-24

  Ro 3306 is a selective CDK1 inhibitor for controllable G2/M arrest, cancer cell synchronization, and DNA repair mechanism study. This article explains how to use its timing-dependent biology to separate mitotic effects from homologous recombination phenotypes and interpret findings alongside emerging TopBP1 research.

• NHE1, Olfr2, and Octanal in Atherosclerosis

  2026-08-23

  This Scientific Reports study identifies macrophage NHE1 as a downstream mediator of octanal/Olfr2-driven atherosclerosis, linking calcium-dependent ROS production with NLRP3 inflammasome activation. Using ApoE−/− mice and RAW264.7 macrophages, the authors combine pharmacological inhibition, RNA interference, and calcium chelation to support a mechanistic pathway with implications for cardiovascular research.

• Quercetin in Neuroinflammation: Assay Strategy

  2026-08-22

  Quercetin is more than a PI3K inhibitor: it can serve as a mechanistic probe linking inflammatory signaling, mitochondrial apoptosis, and neural phenotypes. This guide translates recent LPS-model findings into a rigorous, multi-level assay strategy for cancer research and neuroinflammation studies.

• SGC-CBP30 and Super-Enhancer Logic in Lung Cancer

  2026-08-22

  A translational perspective on how SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor, can help test coactivator dependence in super-enhancer-driven lung adenocarcinoma research without overstating preclinical evidence.

8010 records 1/534 page Next 12345 下5页 Last page